Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Are the Key Milestones in the Chronic Pancreatitis (CP) Market’s Growth Trajectory From 2025 To 2034?
In recent times, the market for Chronic Pancreatitis (CP) has witnessed notable growth. Projected to scale from a valuation of $4.91 billion in 2024 to about $5.25 billion in 2025, it carries an anticipated compound annual growth rate (CAGR) of 6.7%. Drivers for growth in the past period have included increasing levels of alcohol consumption, a higher incidence of smoking, genetic factors and family history, enhanced awareness about pancreatic diseases, a rise in the number of diabetes cases connected to pancreatitis, escalating healthcare expenditure, and improved accessibility to healthcare services.
In the coming years, the market for chronic pancreatitis (CP) is projected to observe substantial growth, expanding to $6.72 billion in 2029 with a compound annual growth rate (CAGR) of 6.4%. The projected growth during this forecast period can be linked to factors like the growing elderly population, heightened demand for enzyme replacement treatments, increasing comprehension of the importance of early detection, healthcare infrastructure development in up-and-coming markets, and the invention of new therapeutic methods for pain management. Furthermore, rising research and clinical investigations aimed at pancreatitis cure contributes to the growth. Major upcoming trends during the forecast period include incorporation of artificial intelligence in diagnostic imaging, less invasive surgical procedures, wearable devices for ongoing health tracking, advancements in genetic testing through next-generation sequencing, machine learning application for tracking disease progression, and the creation of smart diagnostic instruments.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21146&type=smp
What Are the Core Growth Drivers Propelling the Chronic Pancreatitis (CP) Market Forward?
The chronic pancreatitis market is expected to expand due to the rising prevalence of alcohol consumption. Drinking alcohol involves the consumption of ethanol-based beverages, most often for leisurely, social, or cultural reasons, but can also result in addiction or health risks if indulged in excessively. Multiple factors, including growing social acceptance, urbanization, lifestyle modifications, and stress coping mechanisms, particularly among younger demographics, fuel the rise in alcohol consumption. Chronic pancreatitis is induced by alcohol consumption as it initiates inflammation and harm to the pancreatic cells, resulting in fibrosis, duct obstructions, and long-term malfunctions due to harmful metabolic byproducts. For example, in December 2023, as per data published by Kirin Holdings Company Limited, a Japanese beer and beverage holding firm, the total worldwide beer consumption in 2022 increased by approximately 5.4 million kiloliters (equal to roughly 8.5 billion 633ml bottles) compared to 2021, reaching approximately 192.1 million kiloliters. This 2.9% increase is credited to the mitigation of the impact of COVID-19, totaling to approximately 303.5 billion 633ml bottles. Hence, the rise in alcohol consumption is propelling the growth of the chronic pancreatitis market.
What Segment Types Define the Chronic Pancreatitis (CP) Market Structure?
The chronic pancreatitis (CP) market covered in this report is segmented –
1) By Treatment: Analgesic, Artificial Digestive Enzyme, Protein Supplements, Steroids, Antibiotics, Other Treatments
2) By Diagnosis: Computed Tomography (CT) Scan, Magnetic Resonance Cholangiopancreatography, Ultrasound Sonography, Other Diagnosis
3) By Route Of Administration: Oral, Parenteral
4) By End User: Hospitals, Homecare, Other End Users
Subsegments:
1) By Analgesic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Opioids
2) By Artificial Digestive Enzyme: Pancrelipase, Pancreatin
3) By Protein Supplements: Branched-Chain Amino Acids (BCAA), Whey Protein
4) By Steroids: Prednisone, Dexamethasone
5) By Antibiotics: Ciprofloxacin, Metronidazole
6) By Other Treatments: Endoscopic Treatment, Surgery
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21146&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Chronic Pancreatitis (CP) Market?
North America was the largest region in the chronic pancreatitis (CP) market in 2024. The regions covered in the chronic pancreatitis (cp) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which Emerging Trends that Are Influencing theChronic Pancreatitis (CP) Industry Evolution?
Key players in the chronic pancreatitis market are making strides in technological evolution, particularly in enzyme replacement therapy, aimed at managing exocrine pancreatic insufficiency (EPI) related to chronic pancreatitis. This therapy involves the consumption of oral pancreatic enzymes that aid in digestion for patients whose pancreatic functionality is compromised. For example, results were revealed from the Phase 2 SPAN clinical trial by First Wave BioPharma Inc, a US-based clinical-stage biopharmaceutical company, in July 2023. The trial investigated adrulipase, an enhanced enteric microgranule delivery formulation for treating EPI in patients suffering from cystic fibrosis (CF) and chronic pancreatitis. Adrulipase is a recombinant lipase enzyme procured from the Yarrowia lipolytica yeast and is administered as an oral non-systemic biologic capsule. It is designed to disintegrate fat molecules in the EPI patient’s digestive tract, enabling their absorption as nutrients.
View the full report here:
https://www.thebusinessresearchcompany.com/report/chronic-pancreatitis-cp-global-market-report
What Is the Definition of the Chronic Pancreatitis (CP) Market?
Chronic pancreatitis (CP) is a long-lasting, progressive inflammatory condition of the pancreas that causes permanent damage to its structure and function. The disease is marked by persistent inflammation, fibrosis (scarring), and the eventual deterioration of the pancreas’s ability to produce digestive enzymes and hormones such as insulin.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21146
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model